Evista (raloxifene) is now approved to TREAT osteoporosis

November 1999

Evista (raloxifene) is now approved to TREAT osteoporosis...it used to be approved only for PREVENTION.

Evista is a "selective estrogen." It acts like estrogen to prevent bone loss...but it doesn't stimulate the uterus or breast.

New research shows that Evista decreases vertebral fractures up to 50%...in postmenopausal women who take it for 3 years.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote